Nido Biosciences Secures $109M for Neuroscience Research
Precision neuroscience startup Nido Biosciences has emerged from stealth mode with $109 million in funding and a Phase I study already underway. Belgian biotech Dualyx has raised $44 million in financing to take its first Treg candidate into a Phase I study in the second half of 2024. Gilead and Arcus are expanding their partnership to include inflammation targets. UniQure has sold part of its Hemgenix royalty rights for up to $400 million in cash. President Biden intends to nominate Monica Bertagnolli, currently leading the National Cancer Institute, as the head of the National Institutes of Health. The FDA has issued a complete response letter to Byondis, rejecting its pitch for a potential breast cancer therapy. Fulcrum Therapeutics has recruited Alex Sapir as CEO amid management upheaval and a full clinical hold for its sickle cell program. Verve Therapeutics has unveiled its second PCSK9-targeting program, Verve-102, as part of its wider third-quarter financial results.